2026-06-18

OSINT: Iranian Geopolitical Tensions Escalate, Raising Regional Risk

Silver bear 7.0% vs prior close ($70.70 → $65.78)

Gold -2.82%: significant decline on the session

OSINT: NATO Signals Heightened European Geopolitical Tensions

Oil -3.89%: significant decline on the session

OSINT: US casualties in Iran campaign coincide with record‑high stock market

CFTC SILVER speculators at extreme short: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

OSINT: Trump signs MOU to end Iran conflict, White House says

Oil -1.73%: significant decline on the session

OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

Platinum bear 5.0% vs prior close ($1,790.70 → $1,701.80)

Coffee bear 4.3% vs prior close ($277.85 → $265.80)

Gold -2.24%: significant decline on the session

Oil -3.49%: significant decline on the session

Gold -1.17% - significant selloff

Kansas Winter Wheat: crop water stress detected (2.3σ above baseline) - potential ZW=F supply pressure

BTC open interest +225.2% - OI surge

SOL open interest +162.4% - OI surge

ETH open interest +217.9% - OI surge

ETH open interest -66.5% - OI collapse

BTC open interest -44.1% - OI collapse

SOL open interest -63.0% - OI collapse

BTC open interest +252.4% - OI surge

ETH open interest -67.2% - OI collapse

SOL open interest +305.0% - OI surge

SPYx/USDC has $67.0M volume but only $515K liquidity - thin market, slippage risk

BTC open interest -42.3% - OI collapse

ETH open interest -67.3% - OI collapse

SOL open interest +307.5% - OI surge

ETH DEX volume/liquidity ratio elevated (0.53x): on-chain trade volume 0.53x liquidity

OSINT: DOJ Seeks Court Block on Historic US Reparations Program

ETH DEX volume/liquidity ratio elevated (0.51x): on-chain trade volume 0.51x liquidity

Phase 3 trial terminated early - JOHNSON GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study

Phase 3 trial terminated early - JOHNSON Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in

Phase 3 trial terminated early - ELI A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic

Phase 3 trial terminated early - ELI A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melano

Phase 3 trial terminated early - BRISTOL A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus S

Phase 3 trial terminated early - BIOGEN Natalizumab (Tysabri) Re-Initiation of Dosing

Phase 3 trial terminated early - BIOGEN Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Pati

Phase 3 trial terminated early - BIOGEN A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared

Phase 3 trial terminated early - AMGEN Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Phase 3 trial terminated early - AMGEN AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Phase 3 trial terminated early - AMGEN Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Stati

Phase 3 trial terminated early - AMGEN MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Phase 3 trial terminated early - Medtronic Lumbar Interbody Fusion Using the Telamon® Peek™ Versus the Telamon® Hydrosorb™

Phase 3 trial terminated early - AbbVie A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azaciti

Phase 3 trial terminated early - Merck Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

Phase 3 trial terminated early - Merck Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensa

Phase 3 trial terminated early - Merck Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo f

Phase 3 trial terminated early - Merck Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Phase 3 trial terminated early - Merck Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterole

Phase 3 trial terminated early - PFIZER Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Pati

Phase 3 trial terminated early - PFIZER A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing

Phase 3 trial terminated early - PFIZER A Study to Understand the Long-term Safety and Effects of an Experimental Gene T

Phase 3 trial terminated early - PFIZER A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treat

Phase 3 trial terminated early - PFIZER Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Phase 3 trial terminated early - PFIZER Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk

Phase 3 trial terminated early - ABBOTT Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral

Phase 3 trial terminated early - ABBOTT BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

Phase 3 trial terminated early - ABBOTT Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascul

Phase 3 trial terminated early - ABBOTT Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

Phase 3 trial terminated early - ABBOTT Femtosecond Laser for Cataract Surgery

Phase 3 trial terminated early - GILEAD (mo)BETTA Trial in Transwomen for Optimization of ART

Phase 3 trial terminated early - GILEAD Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic

Debt issued for acquisition financing - deal likely imminent

Debt issued for acquisition financing - deal likely imminent

Debt issued for acquisition financing - deal likely imminent

Activist 13D filing - shareholder value

Debt issued for acquisition financing - deal likely imminent

Debt issued for acquisition financing - deal likely imminent

Debt issued for acquisition financing - deal likely imminent

PORTLAND GENERAL ELECTRIC CO /OR/ search volume spiked +100 pts - unusual interest

LINDE PLC search volume spiked +100 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

GE Vernova Inc. search volume spiked +100 pts - unusual interest

MSFT RSI 18.9 - oversold (crossed below 30)

Strategy Inc search volume spiked +26 pts - unusual interest

GE Vernova Inc. search volume spiked +100 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

LINDE PLC search volume spiked +100 pts - unusual interest

Beat consensus by 55.4% - EPS $0.157 vs $0.101 estimate

Q4-2018: Missed consensus by 19.0% - EPS $0.09 vs $0.1111 estimate

Q1-2026: Missed consensus by 95.9% - EPS $-10.34 vs $-5.2785 estimate

Missed consensus by 2109.8% - EPS $-2.87 vs $0.1428 estimate

Beat consensus by 194.1% - EPS $0.21 vs $0.0714 estimate

Q1-2026: Missed consensus by 45.4% - EPS $-1.61 vs $-1.1076 estimate

Q1-2027: Missed consensus by 55.1% - EPS $0.22 vs $0.4896 estimate

Q1-2027: Beat consensus by 6.9% - EPS $1.39 vs $1.3002 estimate

Q1-2026: Beat consensus by 10.3% - EPS $0.39 vs $0.3535 estimate

Q2-2025: Beat consensus by 5.6% - EPS $0.34 vs $0.3219 estimate

Q3-2026: Missed consensus by 60.5% - EPS $13.91 vs $35.2563 estimate

Q2-2026: Beat consensus by 37.7% - EPS $44.94 vs $32.6402 estimate

Q4-2026: Beat consensus by 26.2% - EPS $42.08 vs $33.3464 estimate

Beat consensus by 14.7% - EPS $-0.81 vs $-0.95 estimate

Q4-2026: Beat consensus by 78.3% - EPS $0.6 vs $0.3366 estimate

Q4-2026: Beat consensus by 52.8% - EPS $1.26 vs $0.8248 estimate

Q4-2025: Beat consensus by 43.5% - EPS $0.2 vs $0.1394 estimate

Beat consensus by 86.3% - EPS $0.19 vs $0.102 estimate

Q3-2025: Beat consensus by 13.7% - EPS $2.47 vs $2.1728 estimate

Q1-2026: Beat consensus by 7.3% - EPS $0.43 vs $0.4006 estimate

Q1-2027: Beat consensus by 20.9% - EPS $-0.21 vs $-0.2655 estimate

Q3-2026: Beat consensus by 15.9% - EPS $1.9 vs $1.6388 estimate

Q2-2026: Beat consensus by 168.5% - EPS $0.25 vs $0.0931 estimate

Q4-2026: Missed consensus by 49.9% - EPS $0.3 vs $0.5993 estimate

Missed consensus by 1766.7% - EPS $-0.85 vs $0.051 estimate

Q2-2025: Beat consensus by 19.8% - EPS $-0.09 vs $-0.1122 estimate

Q3-2025: Missed consensus by 30.7% - EPS $-0.08 vs $-0.0612 estimate

Q3-2025: Missed consensus by 18.8% - EPS $0.48 vs $0.5909 estimate

Q4-1999: Beat consensus by 14.2% - EPS $0.3 vs $0.2626 estimate

Q4-2025: Beat consensus by 7.5% - EPS $0.38 vs $0.3535 estimate

Q1-2026: Missed consensus by 9.8% - EPS $-0.31 vs $-0.2823 estimate

Q4-2025: Beat consensus by 16.5% - EPS $-0.23 vs $-0.2754 estimate

Beat consensus by 31.2% - EPS $-0.15 vs $-0.218 estimate

Q2-2026: Beat consensus by 6.7% - EPS $0.31 vs $0.2905 estimate

Q3-2026: Beat consensus by 22.8% - EPS $0.31 vs $0.2525 estimate

Q3-2026: Beat consensus by 78.2% - EPS $0.45 vs $0.2525 estimate

Q2-2025: Missed consensus by 216.8% - EPS $-0.35 vs $0.2996 estimate

Q1-2026: Missed consensus by 91.7% - EPS $0.01 vs $0.1212 estimate

Missed consensus by 85.1% - EPS $0.03 vs $0.202 estimate

Q4-2025: Missed consensus by 253.0% - EPS $-0.17 vs $0.1111 estimate

Q2-2023: Beat consensus by 49.1% - EPS $1.25 vs $0.8383 estimate

Q4-2023: Beat consensus by 310.2% - EPS $0.87 vs $0.2121 estimate

Q3-2024: Beat consensus by 36.0% - EPS $0.92 vs $0.6767 estimate

Q3-2023: Beat consensus by 21.3% - EPS $1.25 vs $1.0302 estimate

Q1-2026: Beat consensus by 26.8% - EPS $16.79 vs $13.2411 estimate

Q4-2025: Missed consensus by 19.3% - EPS $11.45 vs $14.1905 estimate

Q2-2025: Beat consensus by 40.1% - EPS $14.36 vs $10.2515 estimate

Q3-2025: Beat consensus by 16.3% - EPS $13.19 vs $11.3423 estimate

Q4-2025: Missed consensus by 38.6% - EPS $-1 vs $-0.7217 estimate

Beat consensus by 11.9% - EPS $-0.45 vs $-0.511 estimate

Q2-2026: Beat consensus by 10.3% - EPS $-0.43 vs $-0.4795 estimate

Q1-2027: Beat consensus by 49.7% - EPS $-0.2 vs $-0.3978 estimate

Q1-2026: Beat consensus by 10.9% - EPS $0.64 vs $0.5771 estimate

Beat consensus by 120.0% - EPS $0.03 vs $-0.1497 estimate

Q3-2026: Beat consensus by 162.7% - EPS $0.29 vs $-0.4624 estimate

Missed consensus by 14.6% - EPS $-118800 vs $-103626 estimate

Missed consensus by 24.7% - EPS $-91800 vs $-73629 estimate

Missed consensus by 22.3% - EPS $-113400 vs $-92718 estimate

Bond issued at elevated rate 7.5% - credit-stress signal

Bond issued at elevated rate 5.405% - credit-stress signal

Bond issued at elevated rate 4.8% - credit-stress signal

Bond issued at elevated rate 6.25% - credit-stress signal

Bond issued at elevated rate 6.25% - credit-stress signal

Bond issued at elevated rate 4.8% - credit-stress signal

MSFT RSI 17.5 - oversold (crossed below 30)

Strategy Inc search volume spiked +26 pts - unusual interest

GE Vernova Inc. search volume spiked +100 pts - unusual interest

LINDE PLC search volume spiked +100 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

Missed consensus by 27.1% - EPS $43.9 vs $60.231 estimate

Q1-2027: Beat consensus by 9.4% - EPS $-1.97 vs $-2.1741 estimate

Q2-2026: Beat consensus by 52.5% - EPS $0.14 vs $0.0918 estimate

Q1-2026: Beat consensus by 47.2% - EPS $-0.04 vs $-0.0758 estimate

Beat consensus by 13.9% - EPS $-2.4 vs $-2.788 estimate

Missed consensus by 9.9% - EPS $-3.7 vs $-3.366 estimate

Beat consensus by 8.9% - EPS $-2.2 vs $-2.414 estimate

Q1-2026: Beat consensus by 109.9% - EPS $1.039 vs $0.4949 estimate

Beat consensus by 6.5% - EPS $-0.58 vs $-0.6206 estimate

Beat consensus by 49.7% - EPS $-0.32 vs $-0.6359 estimate

Beat consensus by 211.9% - EPS $0.63 vs $0.202 estimate

Q1-2026: Beat consensus by 72.3% - EPS $-0.33 vs $-1.1934 estimate

Missed consensus by 17.6% - EPS $-1.8 vs $-1.53 estimate

Beat consensus by 9.5% - EPS $-1.8 vs $-1.989 estimate

Q3-2026: Beat consensus by 6.1% - EPS $-0.06 vs $-0.0639 estimate

Q4-2026: Missed consensus by 309.7% - EPS $-0.404 vs $-0.0986 estimate

Beat consensus by 108.6% - EPS $0.07 vs $-0.816 estimate

Missed consensus by 198.7% - EPS $-1.84 vs $-0.6159 estimate

Large debt issuance - $1.3B due 2030

Bond issued at elevated rate 6.15% - credit-stress signal

Large debt issuance - $1.0B at 4.95% due 2031

Large debt issuance - $7.5B due 2058

Strategy Inc search volume spiked +26 pts - unusual interest

Bond issued at elevated rate 6.0% - credit-stress signal

Bond issued at elevated rate 10.0% - credit-stress signal

Bond issued at elevated rate 5.2% - credit-stress signal

Bond issued at elevated rate 6.5% - credit-stress signal

Bond issued at elevated rate 5.15% - credit-stress signal

Bond issued at elevated rate 5.5% - credit-stress signal

Bond issued at elevated rate 5.68% - credit-stress signal

Bond issued at elevated rate 5.25% - credit-stress signal

Bond issued at elevated rate 5.0% - credit-stress signal

Bond issued at elevated rate 5.25% - credit-stress signal

Large debt issuance - $8.5B at 4.25% due 2028

Bond issued at elevated rate 5.35% - credit-stress signal

Large debt issuance - $2.8B at 3.137% due 2035

Sanofi search volume spiked +77 pts - unusual interest

LINDE PLC search volume spiked +100 pts - unusual interest

GE Vernova Inc. search volume spiked +100 pts - unusual interest

KLA CORP search volume spiked +39 pts - unusual interest

OSINT: DOJ Seeks Court Block on Historic US Reparations Program

OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

DXY +0.72% - dollar strength signal

DXY +0.56% - dollar strength signal

OSINT: UK-China Steel Trade Tensions Rise Amid New Tariff Discussions

DXY +0.33% - dollar strength signal

OSINT: Ukrainian drones strike Moscow, forcing air traffic diversions

OSINT: UK-China Steel Trade Tensions Rise Amid New Tariff Discussions

Financial conditions loosening - NFCI at -0.51, liquidity supportive